Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Biogen agreed to acquire Apellis for $41.00 per share in cash (~$5.6bn) plus a non-transferable CVR tied to SYFOVRE global sales (potential up to $4/share depending on thresholds); closing is expected in Q2 2026. EMPAVELI and SYFOVRE posted combined net sales of $689m in 2025 and are forecast to grow at a mid-to-high teens CAGR through at least 2028; Biogen expects the deal to be increasingly accretive to non-GAAP diluted EPS starting in 2027 and to meaningfully raise non-GAAP EPS CAGR through the end of the decade. Financing will be via cash and borrowings with an intention to fully de-lever by end-2027, and Apellis’ U.S. commercial and nephrology capabilities are expected to accelerate launch readiness for Biogen’s felzartamab (Phase 3).

Analysis

Combining a specialized C3 franchise into a larger immunology platform creates operational optionality beyond headline revenue: most valuable is the ability to redeploy a disciplined, specialty salesforce into transplant centers, dialysis networks and retina clinics where high-touch education and REMS/safety workflows drive uptake. This is not just a revenue uplift — it materially shortens the path from label to routine use because nephrology and retina are referral-driven specialties with concentrated prescribers; capturing a few high-volume centers can move adoption curves meaningfully within 12–24 months.

Second-order beneficiaries are service and product ecosystems tied to intravitreal injections and wet-AMD management: more patients on complement inhibition who convert to neovascular disease increase demand for anti-VEGF agents, retina imaging, and injection consumables — a predictable revenue tail for incumbents in those adjacencies. Conversely, fragmented ex‑US commercialization (different rights/partners) increases execution risk and can create inconsistent global pricing and access, limiting scale and turning planned upside into lumpy regional outcomes.

Key catalysts to watch with direct timing implications are (1) tender/close dynamics and attendant arbitrage spread over the next weeks, (2) regulatory milestones around device/PFS formats and payer coverage decisions in the next 6–12 months, and (3) Phase 3 readouts for the nephrology asset in the ~12–18 month window which will re-rate the combined growth trajectory if positive. Tail risks that could reverse the constructive outlook include a safety signal that tightens REMS or drives utilization offsets, loss of the acquired field team to attrition, or materially slower payer uptake leading to missed commercial thresholds embedded in contingent consideration.

Key Decisions for Investors

• Event-arb: Buy APLS shares to capture the arbitrage spread into deal close (horizon: weeks–months). Hedge regulatory/transaction risk by shorting an equal-dollar amount of broad biotech beta (e.g., IBB ETF) or buying out-of-the-money APLS puts; reward is capture of spread, risk is deal failure which could cause >30% downside.
• Buy BIIB equity or 12–36 month call spread to play accretion + nephrology optionality (horizon: 12–36 months). Use a collar (long calls/sell shorter-term calls) to limit upfront cost; upside if integration + Phase 3 readouts validate expansion, downside if integration fails or deleveraging timeline slips.
• Long REGN (or other major anti‑VEGF incumbents) via 6–18 month call options to capture increased anti‑VEGF demand from downstream conversions to neovascular disease (horizon: 6–18 months). Rationale: second-order increase in treatment episodes; risk is continued low conversion or payer pushback requiring combination therapy adjudication.
• Hedge thesis-level risk by buying puts on regional/commercial partners with ex‑US rights (example: SOBI) or by shorting small-cap complement/renal peers with upcoming binary readouts (horizon: 6–24 months). This protects against slower-than-expected global rollout and pricing pressure; cost of carry is the main drag if rollout proceeds smoothly.